G1 Therapeutics (GTHX) Earns Buy Rating from Analysts at BTIG Research

BTIG Research assumed coverage on shares of G1 Therapeutics (NASDAQ:GTHX) in a report issued on Tuesday morning. The firm issued a buy rating and a $38.00 price target on the stock.

Several other brokerages have also recently commented on GTHX. Zacks Investment Research cut G1 Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 11th. Cowen reiterated a buy rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $31.40.

G1 Therapeutics (NASDAQ:GTHX) traded down $0.25 during trading hours on Tuesday, hitting $19.22. The stock had a trading volume of 84,100 shares, compared to its average volume of 111,918. G1 Therapeutics has a 52 week low of $12.04 and a 52 week high of $28.67.

In related news, major shareholder Medimmune Ventures, Inc. sold 133,906 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $19.75, for a total value of $2,644,643.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Fredric N. Eshelman bought 250,000 shares of G1 Therapeutics stock in a transaction that occurred on Monday, November 13th. The stock was bought at an average price of $19.73 per share, for a total transaction of $4,932,500.00. The disclosure for this purchase can be found here. Insiders sold 541,406 shares of company stock worth $10,746,719 over the last quarter.

A number of hedge funds have recently made changes to their positions in GTHX. American International Group Inc. bought a new stake in G1 Therapeutics in the third quarter valued at approximately $130,000. California State Teachers Retirement System bought a new position in shares of G1 Therapeutics during the 3rd quarter worth approximately $319,000. Schwab Charles Investment Management Inc. bought a new position in shares of G1 Therapeutics during the 3rd quarter worth approximately $364,000. Alps Advisors Inc. bought a new position in shares of G1 Therapeutics during the 2nd quarter worth approximately $444,000. Finally, Bank of New York Mellon Corp bought a new position in shares of G1 Therapeutics during the 3rd quarter worth approximately $568,000. Institutional investors and hedge funds own 43.25% of the company’s stock.

WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/22/g1-therapeutics-gthx-earns-buy-rating-from-analysts-at-btig-research.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit